

# Global Gynecology Drugs Market To Reach \$54.1 Billion By 2028 With A Growth Rate Of 5.4%

*The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!*

LONDON, GREATER LONDON, UNITED KINGDOM, December 24, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



The Business  
Research Company

Gynecology Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033

[The gynecology drugs market size has surged in recent years.](#) It will grow from \$41.56 billion in 2023 to \$43.78 billion in 2024, noting a compound annual growth rate CAGR of 5.4%. Such

“

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to \$54.1 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%.”

*The Business Research  
Company*

growth during the historic period can be attributed to numerous factors like the introduction of drugs with novel mechanisms, a rise in educational tools and awareness on menopause, a rise in long-acting reversible contraceptives, a shift in lifestyles, increasing healthcare awareness and expenditure, government initiatives, and augmented pharmaceutical research and development expenditure.

How is the growth of gynecology drugs market projected in the future years?

In the next few years, leading up to 2028, the gynecology

drugs market size is extrapolated to see committed growth, reaching up to \$54.1 billion. The forecasted compound annual growth rate CAGR is 5.4%. The growth expected in the forecast period is due to factors like the increase in awareness and usage of contraceptives and hormone replacement therapy HRT, age-related rise in gynecological cancers, a spike in ovarian cancer, prevalence of gynecological diseases, further increment in healthcare expenditure, and rising investment to grasp the mechanisms of endometriosis and its treatment.

To get an in-depth understanding of the market, check out the sample report here:  
<https://www.thebusinessresearchcompany.com/sample.aspx?id=4098&type=smp>

### [What drives the growth of the global gynecology drugs market?](#)

One of the main drivers of growth for the gynecological drugs market is the rise in the number of women suffering from ovarian cancer. Ovarian cancer, a type of cancer, originates in the ovaries, an integral part of the female reproductive system. Gynecological drugs significantly contribute to the management of ovarian cancer by offering targeted and effective treatment options thus improving survival rates and enhancing the quality of life for patients. For instance, it is anticipated by Globocan that the global incidence of ovarian cancer will rise to 434,184 by 2040. This growing incidence of ovarian cancer is projected to boost the market for gynecological drugs in the forecast period.

Are there major players to look out for in the gynecology drugs market report?

Major companies operating in the gynecology drugs market include giants like Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Furukawa Electric, Motherson Sumi, LS Cables & Systems, HUBER+SUHNER., Acome, Yazaki Corporation, Fujikura Ltd., Robert Bosch, HELLA GmbH & Co. KGaA, Coroplast Harness Technology Sp. z oo sp. k, EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o., Coroflex Poland Sp. z o.o Sp. k., Eltrim Kable Sp. z o. o, Anixter, Allied Wire & Cable Inc, Emcocables, Navcar S.A.S, Wirex Cable SA, Sistemas de Argentina S.A, ARJ Water Technology LLC, Fajr Al Hind LLC, Haji Commercial Co LLC, Bahra Cables, Coficab Group

Are there new developments to look forward to in this field?

Drug manufacturers are dedicating significant resources in the development of personalized cancer vaccines, including those for gynecological cancers. A few have already reached clinical trial phases. Pharmaceutical companies are amalgamating genetic sequencing and precision medicine to create new drug therapies and cancer treatments customized for specific patients. Moderna announced the result of the ongoing Phase 1 clinical study in patients with both resected adjuvant and unresected advanced solid tumors. The results were positive when mRNA personalized cancer vaccine PCV mRNA-4157 was administered, either alone or in combination with Merck pembrolizumab KEYTRUDA. At present, the vaccine is in phase 2 clinical trial.

Secure the full report here for detailed insights and data:

<https://www.thebusinessresearchcompany.com/report/gynecology-drugs-global-market-report>

So how is the gynecology drugs market segmented, anyway?

The gynecology drugs market covered in this report is segmented as follows -

- 1 By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy
- 2 By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Other Indications
- 3 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the regional insights into the gynecology drugs market?

During the year 2023, North America was the largest region in the gynecology drugs market. Asia-Pacific, however, is projected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are diverse, ranging from Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, to Africa.

Browse Through More Similar Reports By The Business Research Company:

Pharmaceutical Drugs Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report>

Pharmacies and Drug Stores Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report>

Pharmaceutical API Manufacturing Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report>

### [About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham  
The Business Research Company  
+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/770670492>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.